Oral rifampicin in cases of cutaneous leishmaniasis with multiple lesions (A pilot study)

Indian Journal of Dermatology, Venereology and Leprology

Volumn 68, Issue 5, 2002, Pages 272-

  Bumb, R ^a   Mehta, R ^a  

^a S P MEDICAL COLLEGE   (India)

Author keywords

Cutaneous Leishmaniasis (CL); Rifampicin

Indexed keywords

RIFAMPICIN;

ARTICLE; BODY WEIGHT; DRUG EFFECT; HUMAN; PILOT STUDY; RELAPSE; SKIN DEFECT; SKIN LEISHMANIASIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 33745957750     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Bryceson ADM, Hay RJ. Parasitic worms and protozoa. In Rook/Wilkinson/Ebling. Textbook of Dermatology: 6th edition. Vol.2. Blackwell Science Ltd. Oxford London: 1998;1410.
2. Orhan Ozgoxtasi, Baydar Ibrahim. A randomized clinical-trial of topical paromomycin versus oral ketaconazole for treating cutaneous leishmaniasis in Turkey. Int J Dermatol 1997;36:61-63.
3. Aliz Momeni, Tahmores Jalayer, et al. Treatment of cutaneous leishmaniasis with itraconazole. Arch Dermatol 1996;136:784-786.
4. Bahamadan (A, Tollab TM. Terbinofine in the treatment of cutaneous leishmaniasis: a pilot study. Int J Dermatol 1997;36:59-60.
5. Vasquez FR. Rifampicin in leishmanias. Arch Dermatol 1977;113:1610-1611.